Glaukos Corp - Asset Resilience Ratio
Glaukos Corp (GKOS) has an Asset Resilience Ratio of 19.30% as of March 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2013–2025)
This chart shows how Glaukos Corp's Asset Resilience Ratio has changed over time. Check Glaukos Corp (GKOS) strategic asset index to assess the company's strategic physical and investment asset allocation.
Liquid Assets Composition Over Time
This chart breaks down Glaukos Corp's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see Glaukos Corp (GKOS) market capitalisation.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $172.44 Million | 19.3% |
| Total Liquid Assets | $172.44 Million | 19.30% |
Asset Resilience Insights
- Good Liquidity Position: Glaukos Corp maintains a healthy 19.30% of assets in liquid form.
- This level provides good financial flexibility while maintaining productive asset deployment.
- The company has significant short-term investments, indicating active treasury management.
Glaukos Corp Industry Peers by Asset Resilience Ratio
Compare Glaukos Corp's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Shenzhen New Industries Biomedical
SHE:300832 |
Medical Devices | 9.95% |
|
Double Medical Technology Inc
SHE:002901 |
Medical Devices | 12.59% |
|
Shanghai MicroPort EV MedTech Co. Ltd. A
SHG:688351 |
Medical Devices | 49.23% |
|
Sinocare Inc
SHE:300298 |
Medical Devices | 3.53% |
|
Vitrolife AB
ST:VITR |
Medical Devices | 7.27% |
|
HOB Biotech Group Corp Ltd
SHG:688656 |
Medical Devices | 2.62% |
|
Imricor Medical Systems Inc
AU:IMR |
Medical Devices | 46.50% |
|
Polynovo Ltd
AU:PNV |
Medical Devices | 0.04% |
Annual Asset Resilience Ratio for Glaukos Corp (2013–2025)
The table below shows the annual Asset Resilience Ratio data for Glaukos Corp.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 21.04% | $187.95 Million | $893.49 Million | +5.72pp |
| 2024-12-31 | 15.32% | $149.29 Million | $974.76 Million | -6.16pp |
| 2023-12-31 | 21.48% | $201.96 Million | $940.41 Million | -0.23pp |
| 2022-12-31 | 21.71% | $233.17 Million | $1.07 Billion | -6.05pp |
| 2021-12-31 | 27.76% | $313.34 Million | $1.13 Billion | -2.85pp |
| 2020-12-31 | 30.61% | $307.77 Million | $1.01 Billion | +16.98pp |
| 2019-12-31 | 13.63% | $111.55 Million | $818.40 Million | -39.84pp |
| 2018-12-31 | 53.47% | $110.67 Million | $206.97 Million | -3.52pp |
| 2017-12-31 | 56.99% | $94.51 Million | $165.84 Million | -9.45pp |
| 2016-12-31 | 66.43% | $89.27 Million | $134.37 Million | +6.82pp |
| 2015-12-31 | 59.62% | $69.55 Million | $116.66 Million | +59.39pp |
| 2014-12-31 | 0.23% | $60.00K | $26.02 Million | +0.04pp |
| 2013-12-31 | 0.19% | $60.00K | $30.88 Million | -- |
About Glaukos Corp
Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, develops therapies for the treatment of glaucoma, corneal disorders, and retinal diseases in the United States and internationally. It offers iStent and iStent inject W micro-bypass stents designed to treat mild-to-moderate open-angle glaucoma through the restoration of the natural physiologic outflow pathways for a… Read more